Lead compounds like psilocybin,
ketamine, and DMT are not patentable.
Companies are taking lead compounds, and using standard pharma processes to create compounds that can be patented.
There is a vast number of these potential compounds, almost infinite, and these standard processes are slow and resource heavy.
The odds of finding a viable, patentable compound in a reasonable timeframe are very slim.
Discovery and optimisation processes that traditionally take years can be compressed into days.
We use a range of different AI-driven models to reduce the 'drug candidate search problem'. For example, we can extract insights from millions of experimental affinity measurements to predict the binding of small molecules to proteins. This allows us to analyse a very large chemical space - billions and billions of compounds - to identify a small subset with high specificity.
We also use novel computational methods to evolve the work of medicinal chemists, reducing the number of steps required to make each compound.
We have recently applied these advanced methods to biometrical discovery, and are now bringing this game changing technology to psychedelic medicine.
Our team has a stellar track record, building and exiting AI companies that have superhuman capabilities to detect complex patterns in data.
Dr. Richard Dallaway
Richard's expertise in AI spans 30 years from his undergraduate in AI, and his DPhil in machine learning at the University of Sussex. He has pioneered the use of deep-learning, evolutionary AI, among others, in fields as diverse as drug discovery to cancer diagnostics, to finding patterns in retail consumer purchase data. Richard combines his expertise in machine learning with deep knowledge of building and deploying large-scale enterprise software systems. He is a frequent speaker at conferences and a thought leader in the application of AI in scientific discovery.
Dr. Suran Goonatilake OBE
Suran is a visiting professor at the Computer Science Department at University College London (UCL) and co-founder of several deep-tech companies. He did his Phd in machine learning at UCL and along with fellow students co-founded Searchspace, a company that detects "unusual patterns" in financial transactions (e.g. insider-dealing), which was acquired by Warburg Pincus. He is co-editor of two books, "Intelligent Systems for Finance and Business" and "Intelligent Hybrid Systems". Suran was made an officer of the Order of the British Empire (OBE) in 2005.
Chris has been the co-founder of several tech companies, leading product management in digital media and face recognition offerings. He has business development and consulting experience in pharmaceutical, healthcare and technology industries. His academic background in is Physiological Sciences and Drug Pharmacology from University of Newcastle-upon-Tyne Medical School. As an active public speaker on physical and mental health, Chris is a passionate advocate of psychedelic-assisted psychotherapy with deep knowledge and understanding of the industry.